On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American Society of Nephrology (ASN) where they shared additional Phase 3 data for their drug pegcetacoplan in the treatment of C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Apellis Pharmaceuticals showcased a consistent proteinuria reduction of approximately 68% and noted significant reductions across various patient subgroups, including adolescents versus adults, and pre- versus post-transplant patients.
The data also indicated a statistically significant stabilization of eGFR (estimated Glomerular Filtration Rate), a measure of kidney function, with an increase of 6.3 mL/min/1.732.
Additionally, the treatment demonstrated a significant clearance of C3c from renal biopsies, with 71.4% of patients achieving zero intensity staining by the 26th week.
The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its U.S. launch, the IC-MPGN program still presents a valuable opportunity.
With the stock price below $30 a share, the analyst believes that the IC-MPGN program could contribute approximately $13 per share, which translates to an estimated $850 million in peak sales, assuming an 85% probability of success, as per their model.
The analyst's comments reflect confidence in the transformative potential of pegcetacoplan, reiterating the drug's compelling efficacy profile as presented in the recent data. Despite challenges, the firm sees an opportunity for investors to re-engage with Apellis's narrative, especially considering the potential value contribution from the IC-MPGN program.
In other recent news, Apellis Pharmaceuticals announced the acceptance of its Phase 3 VALIANT study for presentation at the American Society of Nephrology Kidney Week.
The study examines the efficacy and safety of pegcetacoplan in treating rare kidney disorders C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis. The trial, which included 124 participants, is the largest single trial conducted for these patient populations.
Apellis Pharmaceuticals reported robust Q2 2024 growth, with its products SYFOVRE and EMPAVELI generating significant revenues. SYFOVRE achieved over half a billion dollars in sales since its launch and $155 million in net product revenue in Q2 2024 alone, while EMPAVELI contributed with $24.5 million in sales.
However, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a final negative opinion on the potential European regulatory approval for SYFOVRE.
Following this setback, Mizuho Securities reduced its price target for Apellis to $39, maintaining a Neutral rating. In contrast, Baird adjusted its price target for Apellis to $92, maintaining an Outperform rating, despite the EU setback.
Stifel also sustained its Buy rating and $84.00 stock price target for Apellis, citing strong performance and demand in the U.S. market. These are recent developments concerning Apellis Pharmaceuticals.
InvestingPro Insights
Apellis Pharmaceuticals' recent data presentation and Citi's reaffirmed Buy rating align with several InvestingPro insights. According to InvestingPro Tips, analysts anticipate sales growth for Apellis in the current year, which supports the positive outlook on the company's drug pipeline, particularly pegcetacoplan. This expectation is further reinforced by the impressive revenue growth of 240.74% over the last twelve months, as reported in the InvestingPro Data.
Despite the optimistic revenue projections, it's worth noting that InvestingPro Tips indicate analysts do not anticipate the company to be profitable this year. This aligns with the article's mention of recent challenges, including the European Union's non-approval of Syfovre and uncertainties surrounding its U.S. launch. The company's operating income margin of -49.8% for the last twelve months further illustrates the current profitability challenges.
However, Apellis' financial position shows some strength, with InvestingPro Data revealing that liquid assets exceed short-term obligations. This could provide the company with the financial flexibility needed to continue developing and commercializing its drug pipeline, including the promising IC-MPGN program highlighted in the article.
For investors considering Apellis, it's important to note that the stock is currently trading near its 52-week low, with a significant 46.49% price decline over the past six months. This aligns with the analyst's observation of weak sentiment surrounding Apellis stocks but may also present a potential entry point for those who believe in the company's long-term prospects.
InvestingPro offers 9 additional tips for Apellis Pharmaceuticals, providing a more comprehensive analysis for interested investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.